Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

Evaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients

Trial Details

NCT ID
NCT07169500
Phase
PHASE1 / PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • CAR-T
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Subjects voluntarily participate in the study and sign the informed consent form (ICF) themselves or through their legal guardian;
  • Confirmed diagnosis of multiple myeloma through flow cytometry or immunohistochemistry;
  • Subjects must have adequate organ function and meet all of the following test results:
  • Serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →